Published in Cell Host Microbe on September 11, 2008
House-to-house human movement drives dengue virus transmission. Proc Natl Acad Sci U S A (2012) 2.32
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog (2012) 2.02
In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis (2011) 1.92
A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog (2011) 1.70
Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol (2009) 1.65
Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol (2010) 1.58
Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A (2010) 1.57
Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog (2010) 1.56
Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol (2011) 1.51
Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology (2011) 1.48
A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog (2009) 1.41
Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol (2010) 1.41
Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog (2012) 1.31
Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe (2009) 1.27
Rapid development of a DNA vaccine for Zika virus. Science (2016) 1.27
Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis (2013) 1.25
Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A (2011) 1.24
Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol (2011) 1.22
Degrees of maturity: the complex structure and biology of flaviviruses. Curr Opin Virol (2012) 1.15
Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology. Viral Immunol (2010) 1.14
Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J Virol (2012) 1.12
Pivotal role of antibody and subsidiary contribution of CD8+ T cells to recovery from infection in a murine model of Japanese encephalitis. J Virol (2011) 1.09
Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination. J Virol (2014) 1.00
A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. J Virol (2012) 0.98
CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J Immunol (2014) 0.98
Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology (2009) 0.97
Tick-borne flaviviruses: dissecting host immune responses and virus countermeasures. Immunol Res (2009) 0.97
Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog (2013) 0.97
Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice. J Virol (2010) 0.95
Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation. Vaccine (2013) 0.95
The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog (2013) 0.94
The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response. PLoS Negl Trop Dis (2015) 0.94
Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines (2013) 0.94
Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis. PLoS One (2012) 0.94
Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E. J Virol (2009) 0.94
Development of a humanized antibody with high therapeutic potential against dengue virus type 2. PLoS Negl Trop Dis (2012) 0.93
Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5. J Gen Virol (2011) 0.93
Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine. Cell Mol Immunol (2015) 0.92
Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing. MBio (2015) 0.92
Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. MBio (2015) 0.91
Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. J Virol (2013) 0.90
Vaccines in development against West Nile virus. Viruses (2013) 0.90
A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virus. J Virol (2012) 0.89
Structure of the St. Louis encephalitis virus postfusion envelope trimer. J Virol (2012) 0.88
Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front Immunol (2012) 0.87
Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog (2014) 0.86
Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes. Virology (2011) 0.85
Capturing a virus while it catches its breath. Structure (2012) 0.85
Spleen Tyrosine Kinase (Syk) Mediates IL-1β Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection. J Biol Chem (2015) 0.84
A fatal yellow fever virus infection in China: description and lessons. Emerg Microbes Infect (2016) 0.84
Defeating dengue: a challenge for a vaccine. Nat Med (2012) 0.83
Dengue virus neutralization in cells expressing Fc gamma receptors. PLoS One (2013) 0.82
Specificities of human CD4+ T cell responses to an inactivated flavivirus vaccine and infection: correlation with structure and epitope prediction. J Virol (2014) 0.82
Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4. Vaccine (2014) 0.82
Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement. PLoS Negl Trop Dis (2013) 0.81
Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Adv Biol (2014) 0.81
A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis. PLoS Pathog (2017) 0.79
Induction of antigen-specific immune responses in mice by recombinant baculovirus expressing premembrane and envelope proteins of West Nile virus. Virol J (2012) 0.79
The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiol Mol Biol Rev (2017) 0.78
Human CD4+ T Helper Cell Responses after Tick-Borne Encephalitis Vaccination and Infection. PLoS One (2015) 0.78
Aluminum hydroxide influences not only the extent but also the fine specificity and functional activity of antibody responses to tick-borne encephalitis virus in mice. J Virol (2013) 0.78
Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine. J Virol (2014) 0.77
Functional analysis of dengue virus (DENV) type 2 envelope protein domain 3 type-specific and DENV complex-reactive critical epitope residues. J Gen Virol (2014) 0.77
A Single Amino Acid Substitution in the M Protein Attenuates Japanese Encephalitis Virus in Mammalian Hosts. J Virol (2015) 0.77
A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations. PLoS One (2016) 0.76
Clinical outcome and genetic differences within a monophyletic Dengue virus type 2 population. PLoS One (2015) 0.76
Immunization with Immune Complexes Modulates the Fine Specificity of Antibody Responses to a Flavivirus Antigen. J Virol (2015) 0.76
The neutralizing capacity of antibodies elicited by parainfluenza virus infection of African Green Monkeys is dependent on complement. Virology (2014) 0.76
Development and Characterization of Monoclonal Antibodies to Yellow Fever Virus and Application in Antigen Detection and IgM Capture Enzyme-Linked Immunosorbent Assay. Clin Vaccine Immunol (2016) 0.76
Genetic and phenotypic properties of vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice. Am J Trop Med Hyg (2014) 0.76
A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease. Antiviral Res (2016) 0.75
Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiol Mol Biol Rev (2016) 0.75
Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus. PLoS Negl Trop Dis (2017) 0.75
Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. Proc Natl Acad Sci U S A (2016) 0.75
Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III. PLoS One (2015) 0.75
Neutralization of Japanese Encephalitis Virus by heme-induced broadly reactive human monoclonal antibody. Sci Rep (2015) 0.75
Identifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to Epitopes in Other Flavivirus Species. PLoS Curr (2016) 0.75
Recombinant domains III of Tick-Borne Encephalitis Virus envelope protein in combination with dextran and CpGs induce immune response and partial protectiveness against TBE virus infection in mice. BMC Infect Dis (2016) 0.75
Modeling the Role of Epitope Arrangement on Antibody Binding Stoichiometry in Flaviviruses. Biophys J (2016) 0.75
Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes. PLoS Negl Trop Dis (2015) 0.75
Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development. Front Microbiol (2017) 0.75
Characterization and epitope mapping of Dengue virus type 1 specific monoclonal antibodies. Virol J (2017) 0.75
Dengue and dengue hemorrhagic fever. Clin Microbiol Rev (1998) 19.59
Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis (2000) 11.44
Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Global spread and persistence of dengue. Annu Rev Microbiol (2008) 6.44
A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus. Virology (1956) 6.41
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
A structural perspective of the flavivirus life cycle. Nat Rev Microbiol (2005) 5.02
Prospects for a dengue virus vaccine. Nat Rev Microbiol (2007) 4.99
Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res (2003) 4.90
B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol (2003) 4.87
Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg (1988) 4.65
The complement system in regulation of adaptive immunity. Nat Immunol (2004) 4.58
Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol (2001) 4.27
Antibody-enhanced dengue virus infection in primate leukocytes. Nature (1977) 4.18
Structure of the immature dengue virus at low pH primes proteolytic maturation. Science (2008) 3.86
Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology (1994) 3.82
Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology (1998) 3.80
Proteolytic activation of tick-borne encephalitis virus by furin. J Virol (1997) 3.78
Structures of immature flavivirus particles. EMBO J (2003) 3.62
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
Structure of West Nile virus. Science (2003) 3.48
Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet (1996) 3.30
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science (2008) 3.26
The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe (2007) 3.25
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol (2006) 2.79
Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol (2004) 2.64
Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis (2006) 2.52
The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology (1992) 2.48
VIPERdb: a relational database for structural virology. Nucleic Acids Res (2006) 2.46
Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity (2008) 2.43
Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology (2007) 2.40
Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J Gen Virol (1991) 2.34
Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol (2006) 2.33
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
Antigenic structure of flavivirus proteins. Adv Virus Res (2003) 2.15
Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann N Y Acad Sci (2001) 2.13
Yellow fever vaccine. Expert Rev Vaccines (2005) 2.13
Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog (2008) 2.00
Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol (2008) 1.98
A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature (1986) 1.94
The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol (2006) 1.93
Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol (2006) 1.91
West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A (2006) 1.83
Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice. Arch Virol (1994) 1.80
Dengue in Vietnamese infants--results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis (2008) 1.78
Structure of immature West Nile virus. J Virol (2007) 1.77
Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol (2005) 1.75
Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol (2005) 1.72
Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med (2008) 1.67
Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol (2001) 1.63
Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J Med Virol (1995) 1.58
A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol (2001) 1.54
Complement receptor mediates enhanced flavivirus replication in macrophages. J Exp Med (1983) 1.51
Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis (2004) 1.46
A multi-hit model for the neutralization of animal viruses. J Gen Virol (1978) 1.41
Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe (2007) 1.37
Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother (2007) 1.30
Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on viral fate. J Gen Virol (1984) 1.29
Dengue and yellow fever--challenges for the development and use of vaccines. N Engl J Med (2007) 1.27
Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg (1988) 1.26
West Nile virus envelope protein inhibits dsRNA-induced innate immune responses. J Immunol (2007) 1.26
The neutralizing antibody response against West Nile virus in naturally infected horses. Virology (2006) 1.26
Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol (2008) 1.26
Probing the flavivirus membrane fusion mechanism by using monoclonal antibodies. J Virol (2007) 1.21
Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J Gen Virol (1995) 1.19
Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine (2000) 1.14
Tick-borne encephalitis and the impact of vaccination. Arch Virol Suppl (2004) 1.03
Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol (2008) 1.01
Manipulation of cell surface macromolecules by flaviviruses. Adv Virus Res (2003) 0.98
Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. Trends Mol Med (2003) 0.93
West Nile 25A virus infection of B-cell-deficient ((micro)MT) mice: characterization of neuroinvasiveness and pseudoreversion of the viral envelope protein. J Gen Virol (2008) 0.83
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A (2006) 8.27
Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87
Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A (2002) 5.17
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
A structural perspective of the flavivirus life cycle. Nat Rev Microbiol (2005) 5.02
Herpesvirus latency confers symbiotic protection from bacterial infection. Nature (2007) 4.27
Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol (2003) 4.11
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood (2008) 3.89
Structure of the immature dengue virus at low pH primes proteolytic maturation. Science (2008) 3.86
Conformational changes of the flavivirus E glycoprotein. Structure (2004) 3.66
Structures of immature flavivirus particles. EMBO J (2003) 3.62
Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol (2005) 3.59
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature (2010) 3.49
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Structure of West Nile virus. Science (2003) 3.48
Role of CD8+ T cells in control of West Nile virus infection. J Virol (2004) 3.40
Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol (2005) 3.31
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science (2008) 3.26
The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe (2007) 3.25
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol (2006) 3.15
PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol (2006) 3.13
Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc Natl Acad Sci U S A (2010) 2.97
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol (2011) 2.85
Placement of the structural proteins in Sindbis virus. J Virol (2002) 2.81
Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol (2008) 2.62
Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathog (2010) 2.62
IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol (2012) 2.62
Crystal structure of the West Nile virus envelope glycoprotein. J Virol (2006) 2.61
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol (2006) 2.57
Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathog (2007) 2.54
CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol (2006) 2.44
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
West Nile virus infection and immunity. Nat Rev Microbiol (2013) 2.40
IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog (2010) 2.39
Structural changes of envelope proteins during alphavirus fusion. Nature (2010) 2.32
CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol (2006) 2.31
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol (2002) 2.26
Infection and injury of neurons by West Nile encephalitis virus. J Virol (2003) 2.25
Picornavirus-receptor interactions. Trends Microbiol (2002) 2.23
Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 2.18
Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system. Science (2014) 2.16
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol (2003) 2.13
Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med (2006) 2.11
Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat Immunol (2003) 2.09
Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell (2006) 2.08
The structure of the RNA-dependent RNA polymerase from bovine viral diarrhea virus establishes the role of GTP in de novo initiation. Proc Natl Acad Sci U S A (2004) 2.05
Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol (2007) 2.03
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog (2008) 2.00
Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog (2007) 1.97
Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol (2005) 1.97
West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A (2006) 1.96
Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. PLoS Pathog (2009) 1.95
In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis (2011) 1.92
Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J Virol (2008) 1.92
Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol (2006) 1.91
Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur J Immunol (2007) 1.89
Accessory protein recruitment motifs in clathrin-mediated endocytosis. Structure (2002) 1.89
Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J Virol (2006) 1.86
Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J (2009) 1.85
Solution structure of dengue virus capsid protein reveals another fold. Proc Natl Acad Sci U S A (2004) 1.85
Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol (2006) 1.84
Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog (2012) 1.84
Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis (2006) 1.84
West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A (2006) 1.83
The crystal structure of coxsackievirus A21 and its interaction with ICAM-1. Structure (2005) 1.82
MR1 antigen presentation to mucosal-associated invariant T cells was highly conserved in evolution. Proc Natl Acad Sci U S A (2009) 1.81
Crystal structure of human enterovirus 71. Science (2012) 1.79
Structure of immature West Nile virus. J Virol (2007) 1.77
Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med (2010) 1.76
Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A (2013) 1.75
Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol (2005) 1.75
A structural and functional perspective of alphavirus replication and assembly. Future Microbiol (2009) 1.72